Coherus Launches YUSIMRY™, a Biosimilar of Humira®, at $995 per Carton in U.S.
YUSIMRY™ (adalimumab-aqvh) product image YUSIMRY™ (adalimumab-aqvh) - list price $995 per carton of two 40 mg/0.8 mL autoinjectorsSee https://www.yusimry.com for...
YUSIMRY™ (adalimumab-aqvh) product image YUSIMRY™ (adalimumab-aqvh) - list price $995 per carton of two 40 mg/0.8 mL autoinjectorsSee https://www.yusimry.com for...
MATFORS, Sweden, July 03, 2023 (GLOBE NEWSWIRE) -- NorthX Biologics (‘NorthX’), a leading Nordic development and manufacturing organisation with a...
Experts in vaccination from Germany, France and Spain, invited by the Bamberg Foundation, met in Berlin to discuss the key...
Hyrimoz® (adalimumab-adaz) high-concentration formulation (HCF) biosimilar offers US patients reduced injection volume in citrate-free formulationAs one of the only adalimumab...
The Belgian Fitness Entrepreneur Dishes on the Pandemic, Stress, and How It Inspired Him to Create Belgium’s First Natural Libido...
MALVERN, Pa., June 30, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused...
Highly experienced international Board Leader joins Emergex as the company grows and progresses clinical development of its pipeline of T...
- V2ACT Therapeutics™, LLC is a joint venture between Genelux Corporation and TVAX Biomedical, Inc. - V2ACT Immunotherapy is a...
Initiation of pivotal Phase 3 trial in non-small cell lung cancer (NSCLC) marks the first landmark in BioNTech’s and OncoC4’s...
The company’s single sign-on and identity governance solutions helped Health and Social Care (HSC) Trust onboard 500 personnel in under...
Vaccines Investor EventVaccines R&D pipeline raises the bar in RSV, influenza, meningitis, and pneumococcal disease Sanofi reaffirms ambition to...
CINCINNATI, Ohio, June 28, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (“Blue Water” or the “Company”) (Nasdaq: BWV), a...
Dengue is a mosquito-borne viral infection listed by WHO as top 10 threat for global health The government grant is...
Booster study successfully met its primary objective, demonstrating non-inferiority to mRNA-vaccine Regulatory pathway will depend upon the outcome of secondary...
Ocean Biomedical’s Inclusion in the Russell 2000® Index and Russell 3000® Index Builds Momentum for Cutting Edge Therapeutic Programs Targeting...
Robert G. Kramer Sr. to Retire Haywood Miller to Serve as Interim CEO GAITHERSBURG, Md., June 27, 2023 (GLOBE NEWSWIRE)...
Joint Venture (JV) combines CENTOGENE's global leadership in multiomics with local insight of Lifera, a biopharmaceutical company wholly-owned by the...
AC Immune Receives FDA Fast Track Designation for Anti-Amyloid-beta Active Immunotherapy, ACI-24.060, to Treat Alzheimer’s Disease Ongoing Phase 1b/2 ABATE...
Complete elimination of viral load in 100% of patients at day 7 vs 6% in placebo (p=.001)Complete elimination of most...
The Phase 3 study of Ovydso was initiated in China in February 2023 and enrolled and dosed 1,200 COVID-19 patients...